This process strengthens antioxidant responses, ultimately preventing osteoclast development,[202] which shows that BACH1 might be worth considering as a therapeutic target for bone destruction diseases such as osteoporosis and rheumatoid arthritis (RA).[204, 205, 206, 207] BACH1 is crucial in bone metabolism by influencing osteoblasts and osteoclasts, highlighting the need for future development of skeletal system‐specific BACH1 inhibitors. The gene discussed is BACH1; the disease is osteoporosis.